Literature DB >> 12750976

Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition.

Janet L Duke1, Deborah P Jones, Noel K Frizzell, Russell W Chesney, Emily B Hak.   

Abstract

A 10-year-old 40-kg African-American female with megacystis microcolon hypoperistalsis syndrome maintained on total parenteral nutrition (TPN), with a history of metabolic bone disease and renal insufficiency, was admitted with a Candida parapsilosis central venous line infection. During her 280-day hospital stay, she had multiple episodes of bacteremia and recurrent candidemia. Furthermore, she developed pathological fractures and hip displacement with osteomyelitis due to Enterobacter. Hypercalcemia and a history of nephrocalcinosis had prevented appropriate dosing of calcium prior to and during the first months of her hospital stay. Pamidronate and chlorothiazide were added to her regimen. The urinary calcium to creatinine ratio and ionized calcium decreased. The pamidronate dose was increased to 60 mg once a week and was well tolerated. Daily calcium was added to her TPN solution and was increased to 10 mEq/day by the time of discharge. We conclude that relatively large doses of pamidronate may be required in certain cases of refractory hypercalcemia and are well tolerated in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750976     DOI: 10.1007/s00467-003-1162-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  29 in total

Review 1.  Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis.

Authors:  C Brumsen; N A Hamdy; S E Papapoulos
Journal:  Medicine (Baltimore)       Date:  1997-07       Impact factor: 1.889

Review 2.  Parenteral nutrition-related bone disease.

Authors:  W W Koo
Journal:  JPEN J Parenter Enteral Nutr       Date:  1992 Jul-Aug       Impact factor: 4.016

3.  Osteogenesis imperfecta: Are fractures and growth hormone treatment linked?

Authors:  H Kodama; K Kubota; T Abe
Journal:  J Pediatr       Date:  1998-03       Impact factor: 4.406

4.  Renal failure associated with intravenous diphosphonates.

Authors:  H M Bounameaux; J Schifferli; J P Montani; A Jung; F Chatelanat
Journal:  Lancet       Date:  1983-02-26       Impact factor: 79.321

5.  Intravenous pamidronate in juvenile osteoporosis.

Authors:  N J Shaw; C M Boivin; N J Crabtree
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

6.  Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate.

Authors:  R J Profumo; J C Reese; T M Foy; L R Garibaldi; R E Kane
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

7.  Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma.

Authors:  W Zumkeller; A Jassoy; S Lebek; M Nagel
Journal:  J Pediatr Endocrinol Metab       Date:  2001-05       Impact factor: 1.634

8.  Childhood cancer and hypercalcemia: report of a case treated with pamidronate.

Authors:  M T Kutluk; V Hazar; C Akyüz; A Varan; M Büyükpamukçu
Journal:  J Pediatr       Date:  1997-05       Impact factor: 4.406

9.  Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

10.  Aluminum toxicity in infants and children. American Academy of Pediatrics, Committee on Nutrition.

Authors: 
Journal:  Pediatrics       Date:  1996-03       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.